BioRestorative Therapies Inc
$ 0.23
2.80%
26 Feb - close price
- Market Cap 5,399,000 USD
- Current Price $ 0.23
- High / Low $ 0.25 / 0.22
- Stock P/E N/A
- Book Value 0.28
- EPS -1.46
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.90 %
- ROE -2.08 %
- 52 Week High 2.10
- 52 Week Low 0.19
About
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols that primarily involve adult stem cells. The company is headquartered in Melville, New York.
Analyst Target Price
$9.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-12 | 2025-03-31 | 2024-11-11 | 2024-08-13 | 2024-06-11 | 2024-03-18 | 2023-11-13 | 2023-08-11 | 2023-05-12 | 2023-03-27 |
| Reported EPS | -0.33 | -0.3 | -0.64 | -0.375 | -0.0068 | -0.5 | -0.33 | -0.57 | -0.65 | -0.77 | -1.53 | -1.19 |
| Estimated EPS | -0.38 | -0.38 | -0.34 | -0.5533 | -0.43 | -0.56 | -0.52 | -0.69 | -0.68 | -1.19 | -1.26 | -1.43 |
| Surprise | 0.05 | 0.08 | -0.3 | 0.1783 | 0.4232 | 0.06 | 0.19 | 0.12 | 0.03 | 0.42 | -0.27 | 0.24 |
| Surprise Percentage | 13.1579% | 21.0526% | -88.2353% | 32.2248% | 98.4186% | 10.7143% | 36.5385% | 17.3913% | 4.4118% | 35.2941% | -21.4286% | 16.7832% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BRTX
2026-02-25 12:05:52
This article details 12 health care stocks experiencing significant movement in Wednesday's pre-market session. It lists six gainers, including Quince Therapeutics and LifeStance Health Group, and six losers, such as Edesa Biotech and Fortrea Holdings, along with their respective stock changes and market capitalizations. Some movements are attributed to recent quarterly earnings reports.
2026-02-24 13:51:52
BioRestorative Therapies (NASDAQ: BRTX) announced that IP Australia has allowed a patent application for its ThermoStem® technology, which involves non-naturally occurring 3D brown adipose-derived stem cell aggregates for treating obesity and metabolic disorders. This patent expands the company's global intellectual property protection for a cell-based alternative to GLP-1 drugs. Following the announcement, BRTX stock saw a significant increase of 37.01%.
2026-02-24 13:51:52
BioRestorative Therapies has secured a patent in Australia for its ThermoStem® technology, which uses brown adipose-derived stem cells to treat obesity and metabolic disorders. This innovative cell-based therapy aims to offer improved safety and longer-lasting efficacy compared to existing GLP-1 drugs, strengthening the company's competitive position. BioRestorative is also advancing other stem cell-based treatments for disc and spine disease, as well as exploring opportunities in the BioCosmeceutical sector.
2026-02-20 17:06:19
This article lists 12 healthcare stocks experiencing significant price movements during Friday's intraday session. It highlights both gainers, such as Tandem Diabetes Care and Cardio Diagnostics Hldgs, and losers, including GRAIL and BioRestorative Therapies, detailing their respective percentage changes and market capitalizations. The report notes that some movements are attributed to recent Q4 earnings reports.
2026-02-18 12:51:52
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced the closing of a $5.0 million public offering. The offering included 14,285,715 shares of common stock (or pre-funded warrants) and warrants, priced at $0.35 per share. The company plans to use the net proceeds to fund its BRTX-100 clinical trials, ThermoStem Program research, develop its biocosmeceuticals platform, and for general corporate purposes.
2026-02-17 11:28:09
BioRestorative Therapies (BRTX) has successfully completed a public equity offering, raising approximately $5.0 million in gross proceeds through the sale of common and pre-funded units, each paired with five-year warrants. The company engaged Rodman & Renshaw as its exclusive placement agent for the offering, which generated funds to support clinical trials for BRTX-100, pre-clinical work for ThermoStem, biocosmeceuticals development, and general corporate needs.
